CN115068445B - Light-stable astaxanthin nano-particles and preparation method thereof - Google Patents
Light-stable astaxanthin nano-particles and preparation method thereof Download PDFInfo
- Publication number
- CN115068445B CN115068445B CN202210798254.7A CN202210798254A CN115068445B CN 115068445 B CN115068445 B CN 115068445B CN 202210798254 A CN202210798254 A CN 202210798254A CN 115068445 B CN115068445 B CN 115068445B
- Authority
- CN
- China
- Prior art keywords
- astaxanthin
- solution
- hesperidin
- nano
- particles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229940022405 astaxanthin Drugs 0.000 title claims abstract description 79
- 239000001168 astaxanthin Substances 0.000 title claims abstract description 79
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 title claims abstract description 73
- 235000013793 astaxanthin Nutrition 0.000 title claims abstract description 73
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 title claims abstract description 73
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 50
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 claims abstract description 43
- 229940025878 hesperidin Drugs 0.000 claims abstract description 42
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 claims abstract description 41
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 claims abstract description 41
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 claims abstract description 41
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 claims abstract description 41
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 claims abstract description 41
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 claims abstract description 41
- 239000000243 solution Substances 0.000 claims description 63
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 38
- 239000007864 aqueous solution Substances 0.000 claims description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- 238000010438 heat treatment Methods 0.000 claims description 14
- 238000004140 cleaning Methods 0.000 claims description 10
- 239000008367 deionised water Substances 0.000 claims description 10
- 229910021641 deionized water Inorganic materials 0.000 claims description 10
- 238000003756 stirring Methods 0.000 claims description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 6
- 230000002378 acidificating effect Effects 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- 238000001132 ultrasonic dispersion Methods 0.000 claims description 3
- 239000012792 core layer Substances 0.000 claims description 2
- 239000010410 layer Substances 0.000 claims description 2
- 238000010025 steaming Methods 0.000 claims description 2
- 239000002245 particle Substances 0.000 abstract description 18
- 239000000463 material Substances 0.000 abstract description 12
- 239000002775 capsule Substances 0.000 abstract description 10
- 238000000034 method Methods 0.000 abstract description 7
- 239000011259 mixed solution Substances 0.000 abstract description 6
- 238000005538 encapsulation Methods 0.000 abstract description 5
- 239000011162 core material Substances 0.000 abstract description 4
- 239000012296 anti-solvent Substances 0.000 abstract description 3
- 230000003064 anti-oxidating effect Effects 0.000 abstract description 2
- 230000001804 emulsifying effect Effects 0.000 abstract description 2
- 238000001914 filtration Methods 0.000 abstract description 2
- 230000004048 modification Effects 0.000 abstract description 2
- 238000012986 modification Methods 0.000 abstract description 2
- 239000000839 emulsion Substances 0.000 abstract 2
- 102000006395 Globulins Human genes 0.000 abstract 1
- 108010044091 Globulins Proteins 0.000 abstract 1
- 238000013329 compounding Methods 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
- 239000012153 distilled water Substances 0.000 description 17
- 108010018927 conglutinin Proteins 0.000 description 10
- QCUFYOBGGZSFHY-UHFFFAOYSA-N depsidomycin Chemical compound O=C1C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(NC=O)C(C)CC)C(C)OC(=O)C2CCCNN2C(=O)C(CC(C)C)NC(=O)C2CCCNN21 QCUFYOBGGZSFHY-UHFFFAOYSA-N 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 9
- 238000001816 cooling Methods 0.000 description 7
- 238000003760 magnetic stirring Methods 0.000 description 6
- 239000003960 organic solvent Substances 0.000 description 6
- 238000002390 rotary evaporation Methods 0.000 description 6
- 238000009210 therapy by ultrasound Methods 0.000 description 6
- 239000003963 antioxidant agent Substances 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 239000013543 active substance Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 230000031700 light absorption Effects 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 231100000956 nontoxicity Toxicity 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 241000972773 Aulopiformes Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- XQHIJIKPDBEMSE-WMNSZERYSA-N [(2r,3r,4s,5r,6s)-3,6-dihydroxy-4,5-bis(3-nitropropanoyloxy)oxan-2-yl]methyl 3-nitropropanoate Chemical compound O[C@H]1O[C@H](COC(=O)CC[N+]([O-])=O)[C@@H](O)[C@H](OC(=O)CC[N+]([O-])=O)[C@H]1OC(=O)CC[N+]([O-])=O XQHIJIKPDBEMSE-WMNSZERYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Substances CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 208000003464 asthenopia Diseases 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- PSQYTAPXSHCGMF-BQYQJAHWSA-N beta-ionone group Chemical group CC1=C(C(CCC1)(C)C)/C=C/C(C)=O PSQYTAPXSHCGMF-BQYQJAHWSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 150000001749 carotenones Chemical class 0.000 description 1
- 235000005472 carotenones Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000011258 core-shell material Substances 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000005562 fading Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 125000004387 flavanoid group Chemical group 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- AIONOLUJZLIMTK-UHFFFAOYSA-N hesperetin Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-UHFFFAOYSA-N 0.000 description 1
- AIONOLUJZLIMTK-AWEZNQCLSA-N hesperetin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-AWEZNQCLSA-N 0.000 description 1
- 229960001587 hesperetin Drugs 0.000 description 1
- 235000010209 hesperetin Nutrition 0.000 description 1
- FTODBIPDTXRIGS-UHFFFAOYSA-N homoeriodictyol Natural products C1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 FTODBIPDTXRIGS-UHFFFAOYSA-N 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000012430 stability testing Methods 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/11—Encapsulated compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/35—Ketones, e.g. benzophenone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nanotechnology (AREA)
- Dermatology (AREA)
- Polymers & Plastics (AREA)
- Biomedical Technology (AREA)
- Food Science & Technology (AREA)
- Optics & Photonics (AREA)
- Birds (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Toxicology (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention relates to a light-stable astaxanthin nano particle and a preparation method thereof, and a light-stable astaxanthin nano particle with a shell-core spherical structure is constructed, wherein the core material of the nano particle is astaxanthin, the capsule material is prepared by compounding Confucius floribunda globulin and hesperidin, and the particle size is in the nanometer level. Astaxanthin has extremely strong ability to scavenge free radicals, but has poor photostability and is easily oxidized. The photostability of astaxanthin can be improved by the methods of nanoparticle encapsulation and antioxidation modification. After the conglutin is separated out, the conglutin is used as a main capsule wall material film forming material, and the hesperidin is mainly used for improving the performances of light stability and the like of the particles. The preparation method of the nano-particles comprises the following steps: emulsifying the protein-hesperidin mixed solution and an oil phase containing astaxanthin under a proper stabilizer to form emulsion particles, separating and solidifying the capsule wall material of the emulsion particles by an anti-solvent method, and finally filtering or centrifuging to collect nano particles to obtain the light-stable astaxanthin nano particles.
Description
Technical Field
The invention relates to an astaxanthin nano particle with light stability and a preparation method thereof, belonging to the field of micro-nano particles.
Background
Astaxanthin is a ketocarotenoid widely distributed in nature and is found in marine organisms such as shrimp, crab, salmon and algae. Astaxanthin is a fat-soluble carotenoid with strong antioxidant activity and is known as a super antioxidant. The astaxanthin contains two beta-ionone rings, 11 conjugated double bonds and unsaturated alpha-hydroxy ketone in the molecular structure, has relatively active electronic effect, can provide electrons for free radicals or attract unpaired electrons of the free radicals, and can easily react with the free radicals to remove the free radicals, thereby playing roles of resisting oxidation, ultraviolet rays, wrinkles and the like. Because of the ability of scavenging free radicals, astaxanthin is also a potential drug for treating diseases such as cardiovascular diseases, diabetes, stomach diseases and the like, and can relieve eye fatigue, increase muscle endurance and improve the immunity of human bodies. The method is widely applied to industries such as medical treatment, beauty treatment, health care food and the like. However, astaxanthin has poor photostability, is extremely easily decomposed by visible light, and is discolored and deactivated in several hours under normal light, so that the bioavailability of astaxanthin is low, and the application of astaxanthin is further limited, thus the astaxanthin has important significance for improving the stability of astaxanthin.
Disclosure of Invention
The invention aims to solve the technical problems that: astaxanthin has poor photostability, which results in its limitation in the application process. The invention provides a light-stable astaxanthin nano particle and a preparation method thereof, wherein after astaxanthin is coated by a modified microcapsule, a core material and the surrounding environment can be effectively isolated by a shell of a capsule material, and the added hesperidin can react with free radicals in the environment first, so that the purpose of improving the light stability of the light-stable astaxanthin nano particle is further realized. In the preparation method, the corollin is precipitated by utilizing the property of minimum solubility at isoelectric point, and hesperidin is precipitated by an antisolvent precipitation method to obtain the capsule wall material, and the capsule wall material is coated with astaxanthin to prepare the nano-particles.
The technical proposal is as follows:
a light stable astaxanthin nanoparticle is of a 'shell-core' spherical structure, wherein an inner core layer is astaxanthin, and an outer shell layer contains conglycinin and hesperidin; and the average diameter of the nanoparticles ranges from 200 to 500nm.
The preparation method of the light-stable astaxanthin nano-particles comprises the following steps:
step 2, uniformly mixing the aqueous solution of the conglycinin and the astaxanthin solution, and then dropwise adding the hesperidin aqueous solution under the heating condition;
and 3, dropwise adding the solution obtained in the step 2 into acidic water, uniformly stirring, steaming to remove the solvent, washing and centrifuging the product, and dissolving the product in the water to obtain the astaxanthin nanoparticle solution.
In the step 1, the aqueous solution of the conglutin is obtained by dissolving the conglutin in PBS solution and dispersing; the concentration of the conglycinin is 0.01-0.06g/mL.
In the step 1, the concentration of the astaxanthin solution is 1-4g/L, and the adopted solvent is selected from one of ethanol, chloroform and methanol.
In the step 1, the concentration of the hesperidin aqueous solution is 0.005-0.05wt%, and the hesperidin aqueous solution is prepared by ultrasonic dispersion in water and heating.
In the step 2, the heating condition is 80-90 ℃, the mass ratio of the Confucius floridum to the hesperidin is 3-15:1, and the mass ratio of the Confucius floridum to the astaxanthin is 30-100:1.
In the step 3, the acidic water refers to water with pH of 3.5-5.5; the conditions for washing and centrifuging are: cleaning for 2-5 times at the rotating speed of 3000-5000 r/min.
Advantageous effects
The conglutinin is taken as one of vegetable proteins, is salt-soluble protein, is rich in various amino acids, can supplement skin nutrition, nourish skin, has good moisturizing effect on skin, has film forming property and good emulsifying property, has more favorable sulfhydryl groups on the surface, and can form a stable reticular protein film with good strength and viscoelasticity more easily due to a large number of intermolecular free sulfhydryl interactions when the protein is adsorbed on an interface. The conglutinin as carrier protein has the advantages of safety, no toxicity, no immunogenicity, biodegradability, good biocompatibility and the like, so that the isoelectric point of the conglutinin is 3.7-5, and the conglutinin solution is precipitated by changing the pH value and utilizing the property of the conglutinin solution that the solubility of the conglutinin solution is minimum at the isoelectric point, thereby preparing the microparticle capsule wall.
The nano particle with the core-shell structure takes the conglutinin as a main film forming material, has the advantages of safety, no toxicity, no immunogenicity, biodegradability, good biocompatibility and the like, so the invention utilizes the unique space structure of the conglutinin to load the hydrophobic active substance astaxanthin into the nano particle by an antisolvent precipitation method, can increase the solubility of insoluble substances, has better protective effect on easily oxidized active substances, and can remarkably delay the half life of the easily oxidized active substance.
The hesperidin is also called hesperidin and hesperidin, is formed by combining one molecule of hesperetin with one molecule of aromatic disaccharide glycidyl, is a dihydroflavone, is a natural antioxidant, can be dissolved in dilute alkali and pyridine and hot water with the temperature of more than 70 ℃, and has the effects of reducing cholesterol, resisting oxidation, preventing mildew, reducing blood pressure, resisting viruses, improving body immunity and the like in a human body. Hesperidin is also a basic raw material for preparing flavanoids, flavonoids and dihydrochalcones, natural antioxidants and food additives (such as low-energy sweetener), and has good light resistance and heat resistance.
After the capsule wall material of the astaxanthin nano-particle is subjected to compound modification by using the hesperidin, the natural antioxidation performance of the hesperidin can endow the wall material with multiple functions such as light stabilization and the like so as to improve the defects of easy fading, inactivation and the like of astaxanthin, and improve the bioavailability of the astaxanthin nano-particle.
Drawings
FIG. 1 is a polarized electron microscope image of astaxanthin nanoparticles;
FIG. 2 is a graph showing particle size distribution of the particles of example 2 (A) and comparative example 2 (B);
FIG. 3 is a graph of ultraviolet absorption wavelength of astaxanthin;
FIG. 4 is a standard curve for astaxanthin detection;
fig. 5 is a graph comparing color changes for light stability testing.
Detailed Description
In a typical preparation process of the present patent, the preparation method of the light-stable astaxanthin nanoparticles comprises the following steps:
And 2, adding distilled water into a round-bottom flask containing hesperidin, carrying out ultrasonic treatment for 5min until the hesperidin is uniformly dispersed, and heating and stirring until the solution is transparent.
And step 3, slowly dripping the hesperidin aqueous solution into the mixed solution of the conglycinin and the astaxanthin under the heating condition.
And step 4, slowly dripping the solution into acid water at 600r/min, stirring uniformly, removing the organic solvent by rotary evaporation, cooling to room temperature, adding distilled water again for centrifugal cleaning for a plurality of times, and finally adding distilled water for ultrasonic mixing uniformly to obtain the conglycinin-hesperidin-astaxanthin nanoparticle solution.
In the step 1, the concentration of the conglycinin PBS solution is 0.01-0.06g/mL, and the concentration of the astaxanthin-solvent solution is 1-4g/L; the solvent preferably comprises one of ethanol, chloroform and methanol; the uniformly mixing mode adopts oscillation, stirring or ultrasonic treatment.
In the step 2, the heating temperature is 80-120 ℃.
In the step 3, the heating temperature is 80-90 ℃. The mass ratio of the conglycinin to the hesperidin is 3-15:1, and the mass ratio of the conglycinin to the astaxanthin is 30-100:1.
In the step 4, the pH value of the solution is adjusted to 3.7-5, the cooling temperature is 20-30 ℃, and the centrifugal cleaning conditions are as follows: cleaning for 2-5 times at the rotating speed of 3000-5000 r/min.
Example 1
(1) 0.3g of the conglycinin is dissolved in 10mL of PBS solution, and the conglycinin is completely dispersed by magnetic stirring at 600r/min for 2 h. An astaxanthin-ethanol solution was prepared at a concentration of 1mg/mL, and then 10mL of the astaxanthin solution and 3mL of the conglycinin solution were stirred and mixed uniformly.
(2) 200mL of distilled water is added into a round-bottom flask containing 20mg of hesperidin, and after being subjected to ultrasonic treatment for 5min until the hesperidin is uniformly dispersed, the solution is heated and stirred at 80 ℃ until the solution is transparent.
(3) The hesperidin aqueous solution is slowly dripped into the mixed solution of the conglycinin and the astaxanthin under the heating condition of 80 ℃.
(4) Slowly dripping the solution into deionized water (pH 3.7) with 5 times of volume at 600r/min, stirring uniformly, removing the organic solvent by rotary evaporation, cooling to 25 ℃, adding distilled water 3000r/min again, centrifugally cleaning for 2 times, adding distilled water, and mixing uniformly by ultrasonic to obtain the conglycinin-hesperidin-astaxanthin nanoparticle solution.
Example 2
(1) 0.3g of the conglycinin is dissolved in 10mL of PBS solution, and the conglycinin is completely dispersed by magnetic stirring at 600r/min for 2 h. An astaxanthin-acetone solution was prepared at a concentration of 3.3mg/mL, and then 10mL of the astaxanthin solution and 1mL of the conglycinin solution were stirred and mixed uniformly.
(2) 200mL of distilled water is added into a round-bottom flask containing 28mg of hesperidin, and after being subjected to ultrasonic treatment for 5min until the hesperidin is uniformly dispersed, the solution is heated and stirred at 100 ℃ until the solution is transparent.
(3) The hesperidin aqueous solution is slowly dripped into the mixed solution of the conglycinin and the astaxanthin under the heating condition of 85 ℃.
(4) Slowly dripping the solution into deionized water (pH 4) with the volume of 5 times at 600r/min, stirring uniformly, removing the organic solvent by rotary evaporation, cooling to 25 ℃, adding distilled water for centrifugal cleaning for 2 times at 5000r/min again, adding distilled water, and mixing uniformly by ultrasonic waves to obtain the conglycinin-hesperidin-astaxanthin nanoparticle solution.
Example 3
(1) 0.3g of the conglycinin is dissolved in 10mL of PBS solution, and the conglycinin is completely dispersed by magnetic stirring at 600r/min for 2 h. An astaxanthin-ethanol solution was prepared at a concentration of 5mg/mL, and then 10mL of the astaxanthin solution and 1mL of the conglycinin solution were stirred and mixed uniformly.
(2) 200mL of distilled water is added into a round-bottom flask containing 41mg of hesperidin, and after being subjected to ultrasonic treatment for 5min until the hesperidin is uniformly dispersed, the solution is heated and stirred at 110 ℃ until the solution is transparent.
(3) The hesperidin aqueous solution is slowly dripped into the mixed solution of the conglycinin and the astaxanthin under the heating condition of 90 ℃.
(4) Slowly dripping the solution into deionized water (pH 4.3) with 5 times of volume at 600r/min, stirring uniformly, removing the organic solvent by rotary evaporation, cooling to 27 ℃, adding distilled water again at 5000r/min for centrifugal cleaning for 3 times, and finally adding distilled water for ultrasonic mixing uniformly to obtain the conglycinin-hesperidin-astaxanthin nanoparticle solution.
Comparative example 1
The difference from example 1 is that: the capsule wall material of the astaxanthin nano-particle is not added with hesperidin.
(1) 0.3g of the conglycinin is dissolved in 10mL of PBS solution, and the conglycinin is completely dispersed by magnetic stirring at 600r/min for 2 h. An astaxanthin-ethanol solution was prepared at a concentration of 1mg/mL, and then 10mL of the astaxanthin solution and 3mL of the conglycinin solution were stirred and mixed uniformly.
(2) Slowly dripping the solution into deionized water (pH 3.7) with 5 times of volume at 600r/min, stirring uniformly, removing the organic solvent by rotary evaporation, cooling to 25 ℃, adding distilled water 3000r/min again for centrifugal cleaning for 2 times, and finally adding distilled water for ultrasonic mixing uniformly to obtain the conglycinin-astaxanthin nanoparticle solution.
Comparative example 2
The difference from example 1 is that: the deionized water in step 4 had a pH of 8.5.
(1) 0.3g of the conglycinin is dissolved in 10mL of PBS solution, and the conglycinin is completely dispersed by magnetic stirring at 600r/min for 2 h. An astaxanthin-ethanol solution was prepared at a concentration of 1mg/mL, and then 10mL of the astaxanthin solution and 3mL of the conglycinin solution were stirred and mixed uniformly.
(2) 200mL of distilled water is added into a round-bottom flask containing 20mg of hesperidin, and after being subjected to ultrasonic treatment for 5min until the hesperidin is uniformly dispersed, the solution is heated and stirred at 80 ℃ until the solution is transparent.
(3) The hesperidin aqueous solution is slowly dripped into the mixed solution of the conglycinin and the astaxanthin under the heating condition of 80 ℃.
(4) Slowly dripping the solution into deionized water (pH 8.5) with 5 times of volume at 600r/min, stirring uniformly, removing the organic solvent by rotary evaporation, cooling to 25 ℃, adding distilled water 3000r/min again, centrifugally cleaning for 2 times, adding distilled water, and mixing uniformly by ultrasonic to obtain the conglycinin-hesperidin-astaxanthin nanoparticle solution.
1. Nanoparticle morphology testing, particle size and encapsulation efficiency testing
The median particle diameter and the particle diameter range of the nanoparticles prepared in examples and comparative examples were measured by a laser particle sizer after the nanoparticles were diluted with deionized water to a certain concentration.
Diluting the prepared nano particles with deionized water to a certain concentration, performing ultrasonic dispersion for 1min under the power of 100W, sucking the droplets onto a glass slide by using a dropper, and observing the morphological characteristics of the nano particles by using an electron microscope after the cover glass is modified. A micrograph of the nanoparticles of example 1 is shown in figure 1. From the microscopic photograph, the astaxanthin nano-particles prepared in example 1 have better dispersion performance and are in the form of particles.
The encapsulation efficiency of astaxanthin was calculated for the nanoparticles of examples and comparative examples by: filtering the nanoparticle reaction stock solution to obtain a solutionThe absolute ethyl alcohol is fixed to volume to 500M L, 10mL is taken to test the light absorption intensity of astaxanthin at 489nm wavelength, the mass M of astaxanthin in filtrate is calculated according to the light absorption intensity, and the total mass M of astaxanthin added in experiments is calculated 0 . The calculation formula of the encapsulation efficiency delta is as follows: δ=100× (M 0 -M)/M
The results are shown in Table 1:
TABLE 1
As can be seen from the results of Table 1, the astaxanthin nanoparticles prepared by using the composite wall material of conglycinin and hesperidin have an average particle size of about 400nm and a smaller particle size. The nano particles prepared by the method have good encapsulation efficiency which is up to more than 90 percent. Whereas the particle size distribution of example 1 is shown in the regions a and B of fig. 2 as compared with that of comparative example 2, it can be seen that the particle size distribution prepared in example 1 is narrower (region a), focusing mainly on the range of 200-500nm, whereas in comparative example 2 (region B), since the pH of the preparation conditions is above the isoelectric point of the metacarphedulins, it is not easy to obtain uniform particles by precipitation, resulting in a smaller overall particle size and a wider distribution, making it impossible to effectively achieve the formation of coated particles and the coating of astaxanthin.
FIG. 3 shows that the absorbance curves of astaxanthin standards at different concentrations are well-aligned, as shown in FIG. 4, with a maximum absorption wavelength of astaxanthin in absolute ethanol around 489 nm.
2. Light stability test
Dispersing the nano particles prepared by experiment into deionized water to prepare aqueous dispersion with concentration of 10ppm, putting the aqueous dispersion into a transparent bottle, and placing the transparent bottle into an ultraviolet radiation box (sun-proof CPS+, 450W/m) 2 The color change value was measured after 30min at 45℃to measure the light stability of the sample.
As can be seen from fig. 2, the astaxanthin nanoparticle dispersion liquid prepared in example 1 and comparative example 1 was pale red, and after 30 minutes of uv irradiation, the color change of the sample of example 1 was not significant, whereas the color of the sample prepared in comparative example 1 was discolored. It is explained that the hesperidin added to the nanoparticle capsule of example 1 plays an antioxidant role, thereby protecting the filler astaxanthin from oxidation and improving its light stability.
Claims (2)
1. The light-stable astaxanthin nano-particle is characterized by having a 'shell-core' spherical structure, wherein an inner core layer is astaxanthin, and an outer shell layer contains conglycinin and hesperidin; and the average diameter of the nano particles is in the range of 200-500nm;
the preparation method of the light-stable astaxanthin nano-particles comprises the following steps:
step 1, respectively obtaining an aqueous solution of the conglycinin, an astaxanthin oil solution and an aqueous solution of the hesperidin;
step 2, uniformly mixing the aqueous solution of the conglycinin and the astaxanthin solution, and then dropwise adding the hesperidin aqueous solution under the heating condition;
step 3, dropwise adding the solution obtained in the step 2 into acidic water, uniformly stirring, steaming to remove the solvent, washing and centrifuging the product, and dispersing the product in the water to obtain astaxanthin nanoparticle solution;
in the step 1, the aqueous solution of the conglutin is obtained by dissolving the conglutin in PBS solution and dispersing; the concentration of the conglycinin is 0.01-0.06g/mL;
in the step 1, the concentration of the astaxanthin solution is 1-4g/L, and the adopted solvent is selected from one of ethanol, chloroform and methanol;
in the step 1, the concentration of the hesperidin aqueous solution is 0.005-0.05wt%, and the hesperidin aqueous solution is prepared by ultrasonic dispersion in water and heating;
in the step 2, the heating condition is 80-90 ℃, the mass ratio of the Confucius floridum to the hesperidin is 3-15:1, and the mass ratio of the Confucius floridum to the astaxanthin is 30-100:1.
2. The photostable astaxanthin nanoparticle according to claim 1, wherein in step 3, the acidic water is deionized water having a ph of 3.5-5.5; the conditions for washing and centrifuging are: and cleaning for 2-5 times at the rotating speed of 3000-5000 r/min.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2022106049209 | 2022-05-31 | ||
| CN202210604920 | 2022-05-31 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115068445A CN115068445A (en) | 2022-09-20 |
| CN115068445B true CN115068445B (en) | 2023-05-26 |
Family
ID=83257735
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210798254.7A Active CN115068445B (en) | 2022-05-31 | 2022-07-08 | Light-stable astaxanthin nano-particles and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115068445B (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001316601A (en) * | 2000-05-02 | 2001-11-16 | Fuji Chem Ind Co Ltd | Stable emulsion for coloring and method for preparing the same |
| JP2008110926A (en) * | 2006-10-30 | 2008-05-15 | Fujifilm Corp | Water-dispersible nanoparticle |
| CN107307403A (en) * | 2017-07-12 | 2017-11-03 | 日照职业技术学院 | A kind of astaxanthin micro and nano powders preparation |
| WO2019059661A1 (en) * | 2017-09-22 | 2019-03-28 | 나노다이아랩 주식회사 | Method for preparing cosmetic composition having biologically active substance dispersed therein |
| CN113368006A (en) * | 2021-06-10 | 2021-09-10 | 河南工业大学 | Preparation method and application of high-water-dispersion H-type or J-type aggregate astaxanthin/lactalbumin/chitosan nano compound |
-
2022
- 2022-07-08 CN CN202210798254.7A patent/CN115068445B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001316601A (en) * | 2000-05-02 | 2001-11-16 | Fuji Chem Ind Co Ltd | Stable emulsion for coloring and method for preparing the same |
| JP2008110926A (en) * | 2006-10-30 | 2008-05-15 | Fujifilm Corp | Water-dispersible nanoparticle |
| CN107307403A (en) * | 2017-07-12 | 2017-11-03 | 日照职业技术学院 | A kind of astaxanthin micro and nano powders preparation |
| WO2019059661A1 (en) * | 2017-09-22 | 2019-03-28 | 나노다이아랩 주식회사 | Method for preparing cosmetic composition having biologically active substance dispersed therein |
| CN113368006A (en) * | 2021-06-10 | 2021-09-10 | 河南工业大学 | Preparation method and application of high-water-dispersion H-type or J-type aggregate astaxanthin/lactalbumin/chitosan nano compound |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115068445A (en) | 2022-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhang et al. | Nanostructures of protein-polysaccharide complexes or conjugates for encapsulation of bioactive compounds | |
| Tan et al. | Combination of copigmentation and encapsulation strategies for the synergistic stabilization of anthocyanins | |
| Tachaprutinun et al. | Preventing the thermal degradation of astaxanthin through nanoencapsulation | |
| Li et al. | Development of a nanoparticle delivery system based on zein/polysaccharide complexes | |
| Arab et al. | Microencapsulation of microbial canthaxanthin with alginate and high methoxyl pectin and evaluation the release properties in neutral and acidic condition | |
| Wang et al. | Stability and bioactivity of carotenoids from Synechococcus sp. PCC 7002 in Zein/NaCas/Gum Arabic composite nanoparticles fabricated by pH adjustment and heat treatment antisolvent precipitation | |
| CN112205628A (en) | Composite condensate with double embedding functions and preparation method and application thereof | |
| JP2013053086A (en) | Microcapsule containing oil and fat and method for producing the same | |
| CN108850790A (en) | A kind of monascorubin microcapsules and preparation method thereof | |
| CN111096956A (en) | Preparation method of pH response intestinal targeting active factor carrying system based on anionic sodium alginate | |
| CN110574931A (en) | microencapsulated low-bitter functional soybean polypeptide and preparation method and application thereof | |
| Shen et al. | Fabrication of bacterial cellulose nanofibers/soy protein isolate colloidal particles for the stabilization of high internal phase pickering emulsions by anti-solvent precipitation and their application in the delivery of curcumin | |
| CN113956500A (en) | Zein composite particles, carrying system, preparation method and application | |
| CN113662183A (en) | Preparation method of emulsion with astaxanthin protection and controlled release effects | |
| Li et al. | Amphiphilic nano-delivery system based on modified-chitosan and ovalbumin: Delivery and stability in simulated digestion | |
| CN107252132B (en) | Casein-carragheen independently fills the preparation method and applications of capsule of nano | |
| CN115068445B (en) | Light-stable astaxanthin nano-particles and preparation method thereof | |
| Tan et al. | Layer-by-layer self-assembled liposomes prepared using sodium alginate and chitosan: Insights into vesicle characteristics and physicochemical stability | |
| CN111296729B (en) | Water-soluble astaxanthin product and preparation method thereof | |
| CN110393683B (en) | Preparation method and application of tea polyphenol micro-nano complex based on protein carrier | |
| CN115607524B (en) | Curcumin-loaded composite nanoparticle and preparation method thereof | |
| CN115025046B (en) | Preparation method and application of gamma-polyglutamic acid/A-type gelatin/EGCG nano-composite | |
| CN115644453A (en) | Method for stabilizing DHA emulsion by soybean polypeptide-polyphenol antioxidant particles | |
| CN111184870A (en) | Preparation method of astaxanthin transporter with gastric juice digestion resistance | |
| CN107550754B (en) | Method for preparing antioxidant composite nano particles by photocatalytic polymerization |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |